5495 results for "*oma"

in 19.61 milliseconds.

• an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses

  an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses

  Study EGAS00001000509

• Spatial Transcriptomic data from Invasive lobular breast carcinoma (ILC)

  Spatial transcriptomic data from Invasive lobular breast carcinoma (ILC) Djerroudi et al, Nature Communication

  Study EGAS50000001735

• Arcagen - Gynecologic cancer domain

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting the dataset that contain NGS files from patients with rare ovarian cancer and primary peritoneal cancer and/or fallopian-tube cancer, including low grade serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma; and other rare cancers such as sex cord tumors, germ cell tumor, yolk sac tumor, and malignant/immature teratoma (n=94).

  Study EGAS50000000900

• Diverse Cellular Composition in Alveolar Rhabdomyosarcoma Revealed by Single Cell RNA Sequencing

  Using single cell RNAseq data to characterize tumor composition and cellular states for Alveolar Rhabdomyosarcoma. We find that that ARMS tumors harbor phenotypically and transcriptionally distinct malignant subpopulations within an immune-influenced microenvironment.

  Study EGAS50000001564

• Low intratumoral macrophage infiltration is a consistent immune microenvironment predictor of poor outcome in lymphoma patients treated with R-CHOP but not Pola-R-CHP

  The lymphoma microenvironment is a key contributor to treatment efficacy and a focus of active investigation. Yet, the adaptive interplay between immune infiltrates, malignant cells and treatment outcomes remains incompletely understood. Currently, little is known about how lymphoma cellular and functional heterogeneity may influence outcomes in patients treated with antibody drug conjugates (ADC), designed for lymphoma-targeted delivery of cytotoxic agents. Here, we evaluated the association of lymphoma immune microenvironment with treatment outcomes using tissue biopsies from 1,279 diffuse large B-cell lymphoma (DLBCL) patients treated with anti-CD20+chemo or Pola-R-CHP as front line therapies.

  Study EGAS50000001723

• PTEN homozygous deletion is a negative prognostic factor in Tumor Treating Fields-treated glioblastoma, IDH wildtype patients

  This study investigates genomic determinants of outcome in glioblastoma, IDH-wildtype patients treated with Tumor Treating Fields (TTFields) in addition to standard radiochemotherapy. Tumor tissue from primary glioblastoma at initial diagnosis was profiled using the Illumina TruSight Oncology 500 (TSO500) targeted sequencing panel to characterise somatic alterations. The overarching goal is to provide exploration of genomic determinants of survival and treatment response in TTFields-treated glioblastoma, IDH-wildtype.

  Study EGAS50000001469

• E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma

  Invasive lobular breast carcinoma (ILC) shows specific stromal features, T lymphocyte infiltration (TIL) being associated with poor prognosis. Here, we reveal the involved mechanism by performing single cell RNA sequencing, combined immunohistochemistry, deconvolution of bulk RNA sequencing from large retrospective ILC series, and functional assays using primary cells. We show that ILC accumulates FAP+ inflammatory cancer-associated fibroblasts (iCAF) through a previously undescribed mechanism mediated by E-cadherin/CDH1 on CAF plasticity. Indeed, CDH1 inactivation in ILC cancer cells prevents differentiation of iCAF into myofibroblastic CAF (myCAF), leading to iCAF accumulation. In turn, iCAF attract TILs into the tumor center and shape their spatial organization in ILC. Subsequently, CDH1-inactivated ILC cancer cells promote immune escape by lack of retention and activation of ITGAE-expressing resident memory CD8+ T lymphocytes (TRM). Hence, our study uncovers reciprocal interactions between CDH1-inactivated cancer cells, iCAF and CD8+ TRM, gaining insight into the underlying mechanism associated with the distinctive stromal reaction observed in ILC and revealing why and how TILs have a poor prognosis in ILC patients, a mechanism that can be generalized to other CDH1-inactivated cancer types.

  Study EGAS50000001760

• Single-cell profiling of peripheral blood from treatment-naïve GBM patients and healthy donors.

  Glioblastoma (GBM) induces systemic immune reprogramming characterized by altered circulating myeloid and lymphoid populations. Single-cell profiling of peripheral blood from treatment-naïve GBM patients identified heterogeneous monocyte states, expansion of suppressive myeloid cells, reduced MHC class II expression and distinct GBM-associated immune signatures. These findings support peripheral blood immune profiling as a potential source of biomarkers in GBM.

  Study EGAS00001008497

• Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy

  Diffuse midline glioma, H3 K27-altered (DMG), remains a lethal pediatric brain tumor with limited therapeutic options, and imipridone therapy produces only temporary responses before recurrence. To investigate resistance mechanisms, we performed single-nucleus RNA and chromatin accessibility profiling on 22 postmortem DMG specimens treated with imipridones and/or standard care, alongside functional assays of imipridone sensitivity and mitochondrial activity in DMG cell lines. Imipridone-treated tumors showed reduced mesenchymal transition, decreased myeloid-derived suppressor cells, and downregulation of aberrant enhancer activity associated with H3 K27 alterations. Mechanistically, treatment selected for increased mitochondrial density, turnover, and membrane potential. Together, these findings identify mitochondrial biogenesis as a key marker and driver of imipridone resistance, providing a rationale for combination strategies to improve therapeutic efficacy.

  Study EGAS50000001447

• Arcagen - Skin cancer domain

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting the dataset that contain NGS files patients diagnosed with adnexal carcinoma of the skin, Merkel cells cancer, and malignant melanoma of the uvea (n=49).

  Study EGAS50000000491